72 results on '"Fetsch, Patricia"'
Search Results
2. Supplementary Figure 2 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
3. Supplementary Table 6 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
4. Supplementary Figure S5 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
5. Supplementary Figure 2 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
6. Supplementary Table S1 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
7. Supplementary Table 1 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
8. Supplementary Table 1 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
9. Supplementary Table 2 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
10. Supplementary Table 1 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
11. Supplementary Figure 2 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
12. Supplementary Figure 2 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
13. Supplementary Figure 4 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
14. Supplementary Figure S3 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
15. Supplementary Figure 1 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
16. Supplementary Materials and Methods from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
17. Supplementary Figure 6 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
18. Supplementary Figure 4 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
19. Supplementary Figure 6 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
20. Supplementary Figure 3 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
21. Supplementary Table 6 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
22. Supplementary Table 5 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
23. Supplementary Figure 1 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
24. Supplementary Table 4 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
25. Supplementary Table 2 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
26. Supplementary Table 3 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
27. Supplementary Table 2 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
28. Supplementary Table S2 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
29. Supplementary Table 3 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
30. Supplementary Figure S2 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
31. Supplementary Table 4 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
32. Supplementary Materials and Methods from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
33. Supplementary Figure 5 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
34. Supplementary Figure S4 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
35. Supplementary Table 2 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
36. Supplementary Table S1 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
37. Supplementary Table S2 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
38. Supplementary Figure 1 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
39. Supplementary Figure 5 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
40. Supplementary Figure S1 from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
41. Supplementary Table 4 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
42. Supplementary Methods from Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells
43. Supplementary Figure 3 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
44. Supplementary Figure 1 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
45. Supplementary Table 5 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
46. Supplementary Table 3 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
47. Supplementary Table 4 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
48. Supplementary Table 1 from Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
49. Supplementary Table 2 from Mithramycin Represses Basal and Cigarette Smoke–Induced Expression of ABCG2 and Inhibits Stem Cell Signaling in Lung and Esophageal Cancer Cells
50. Supplementary Table 3 from Mithramycin Represses Basal and Cigarette Smoke–Induced Expression of ABCG2 and Inhibits Stem Cell Signaling in Lung and Esophageal Cancer Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.